ANGN News and Press, Angion Biomedica Corp. From 03/30/21

Angion Biomedica (ANGN): Q4 GAAP EPS of -$1.90 misses by $0.60.Revenue of $0.46M (-34.3% Y/Y) misses by $1.44M.As of December 31, 2020, Angion had cash and cash equivalents totaling $34.6 million.Press Release For further details see: Angion Biomedica EPS misses by $0.60, misses on reve...

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today pro...

Angion Biomedica (ANGN) has completed enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respirato...

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today an...

Angion Biomedica (ANGN) announces that its the lead book-running managers in the company's recent public sale of 5.75M shares have agreed to a partial wavier of a lock-up restriction with respect to about 100K shares held by certain employees.The waiver will take effect on March 23, 2021, and...

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today ann...

Two IPOs are scheduled to raise $1.3 billion in the week ahead. Street research is expected for 14 companies. Lock-up periods will be expiring for six companies. For further details see: U.S. IPO Week Ahead: Health Insurer Oscar Health Leads A 2 IPO Week

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, t...